TW200612983A - Vaccine - Google Patents

Vaccine

Info

Publication number
TW200612983A
TW200612983A TW094119691A TW94119691A TW200612983A TW 200612983 A TW200612983 A TW 200612983A TW 094119691 A TW094119691 A TW 094119691A TW 94119691 A TW94119691 A TW 94119691A TW 200612983 A TW200612983 A TW 200612983A
Authority
TW
Taiwan
Prior art keywords
hpv
composition
types
cancer
vaccine
Prior art date
Application number
TW094119691A
Other languages
Chinese (zh)
Inventor
Serge Debrus
Marie-Therese Martin
Robert John Stephen
Jean Stephenne
Martine Anne Cecile Wettendorff
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/114,301 external-priority patent/US20050287161A1/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of TW200612983A publication Critical patent/TW200612983A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

An immunogenic composition and methods for producing said composition, the composition comprising VLPs from HPV 16 and 18 and at least one other HPV cancer type, the other cancer type being selected from the list consisting of HPV types 31, 45 and 52, wherein the dose of the VLP of the at least one other cancer types is reduced relative to that of HPV 16 or 18.
TW094119691A 2004-06-16 2005-06-14 Vaccine TW200612983A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0413510.9A GB0413510D0 (en) 2004-06-16 2004-06-16 Vaccine
US11/114,301 US20050287161A1 (en) 2002-12-20 2005-04-26 Vaccine

Publications (1)

Publication Number Publication Date
TW200612983A true TW200612983A (en) 2006-05-01

Family

ID=32750044

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094119691A TW200612983A (en) 2004-06-16 2005-06-14 Vaccine

Country Status (15)

Country Link
JP (1) JP2012102132A (en)
KR (1) KR101359943B1 (en)
CN (1) CN1976718B (en)
CY (1) CY1113830T1 (en)
DK (1) DK1758609T3 (en)
ES (1) ES2394448T3 (en)
GB (1) GB0413510D0 (en)
HR (1) HRP20120930T1 (en)
HU (3) HUS1500061I1 (en)
LT (1) LTC1758609I2 (en)
NL (3) NL300771I2 (en)
PT (1) PT1758609E (en)
SI (1) SI1758609T1 (en)
TW (1) TW200612983A (en)
ZA (1) ZA200610057B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2416798B1 (en) * 2009-04-10 2017-09-20 The Johns Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
NZ606949A (en) * 2010-07-15 2015-11-27 British Columbia Cancer Agency Human papillomavirus e7 antigen compositions and uses thereof
CN107188966B (en) 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 Papilloma virus chimeric protein and application thereof
CN114539365B (en) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 Modified human papilloma virus 52 type L1 protein and application thereof
CN114716561B (en) 2021-01-04 2024-03-12 中国医学科学院基础医学研究所 Human papilloma virus 31 chimeric protein and application thereof
CN114716560B (en) 2021-01-04 2024-02-02 中国医学科学院基础医学研究所 Human papilloma virus 18 chimeric protein and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens

Also Published As

Publication number Publication date
HRP20120930T1 (en) 2012-12-31
KR101359943B1 (en) 2014-02-10
CY1113830T1 (en) 2016-06-22
NL300771I1 (en) 2015-12-29
KR20120123617A (en) 2012-11-08
ES2394448T3 (en) 2013-01-31
NL300774I1 (en) 2015-12-29
DK1758609T3 (en) 2012-12-10
NL300773I1 (en) 2015-12-29
NL300773I2 (en) 2015-12-29
JP2012102132A (en) 2012-05-31
SI1758609T1 (en) 2013-01-31
LTC1758609I2 (en) 2017-05-10
CN1976718A (en) 2007-06-06
HUS1500059I1 (en) 2017-10-30
GB0413510D0 (en) 2004-07-21
PT1758609E (en) 2012-12-21
CN1976718B (en) 2012-10-10
HUS1500060I1 (en) 2017-10-30
NL300771I2 (en) 2015-12-29
HUS1500061I1 (en) 2016-01-28
ZA200610057B (en) 2008-02-27
NL300774I2 (en) 2015-12-29

Similar Documents

Publication Publication Date Title
WO2006037787A3 (en) Vlp-antigen conjugates and their uses as vaccines
SG153837A1 (en) Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
MY139031A (en) Vaccine composition comprising virus-like particles of human papillomavirus
TW200612983A (en) Vaccine
WO2005013901A3 (en) Oligomeric compounds and compositions for use in modulation of small non-coding rnas
WO2005056759A3 (en) Methods of generating variant proteins with increased host string content and compositions thereof
MY139500A (en) Optimized expression of hpv 58 l1 in yeast
WO2007024941A3 (en) Polyvalent vaccine
WO2007095976A3 (en) Adjuvant in the form of a lipid-modified nucleic acid
TW200716646A (en) (S)-N-methylnaltrexone
WO2008024302A3 (en) Compounds for treating proliferative disorders
WO2008057550A3 (en) Stabilization of vaccines by lyophilization
MX2011008649A (en) Inactivated dengue virus vaccine with aluminium-free adjuvant.
WO2006076003A3 (en) Vaccinia virus strains
WO2012165815A3 (en) Nano-vehicle derived from tumor tissue, and cancer vaccine using same
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
BRPI0810959A2 (en) "hpv11 l1 protein, polynucleotide, vector, cell, composition, virus-like particle (vlp) hp11, method for producing an hpv l1 protein, vaccine for prevention of acuminate condyloma or hpv infections, use of the protein prevention method of acuminate condyloma or hpv infections and method for prevention of acuminate condyloma or hpv infections.
GB0320020D0 (en) Improved formulation for providing an enteric coating material
MX2022009964A (en) Hpv vaccine.
WO2005058356A3 (en) Methods for porducing storage stable viruses and immunogenic compositions thereof
EP4248992A3 (en) Foot-and-mouth disease vaccine
WO2005017130A3 (en) Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses thereof
BRPI0818718B8 (en) process of preparing a vaccine composition comprising antigen and adjuvant in the form of inverse latex of acrylic acid homopolymer
SG149058A1 (en) Live genetically attenuated malaria vaccine
WO2006105255A3 (en) Cancer vaccines and therapeutic methods